Tempest Therapeutics

Company snapshot

Tempest Therapeutics is a clinical-stage biotechnology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a wide range of tumors. The company’s novel programs range from early research to later-stage investigation in a randomized global study in first-line cancer patients.

• 3 active pipeline program(s) linked via ClinicalTrials.gov.
• 10 US patent(s) indexed to this assignee profile.
• 3 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Tempest Therapeutics. Not investment advice.

• Peer + 0 momentum

  Coherus Oncology

  TA overlap score 25

Recent activity

Latest pipeline, patent, and corporate events for Tempest Therapeutics.

1. Jun 8, 2026 Clinical update

   Part 1 TPST-1120 — Phase 1

2. May 23, 2026 Clinical update

   TPST-1120 — Phase 3

3. May 23, 2026 Clinical update

   TPST-1495 twice daily — Phase 1

4. Feb 4, 2025 Patent grant

   Bicyclic carboxamides and methods of use thereof

5. Oct 24, 2023 Patent grant

   Bicyclic carboxamides and methods of use thereof

View all clinical trial activity →

• What is Tempest Therapeutics?

  Tempest Therapeutics is a pharma organization headquartered in Brisbane, USA. It trades on NYSE under ticker TPST. Primary therapeutic focus areas include Hepatocellular Carcinoma, Hepatocellular Carcinoma (HCC), Solid Tumor. NovaPharmaNews links 3 clinical program(s), 0 drug pro

• Is Tempest Therapeutics publicly traded?

  Yes. Tempest Therapeutics is listed with ticker TPST on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Tempest Therapeutics develop or market?

  We link 1 drug profile(s) where Tempest Therapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/tempest-therapeutics#company-drugs.

• What are the latest developments for Tempest Therapeutics?

  In the last 12 months our linked public records show 3 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Tempest Therapeutics focus on?

  Tempest Therapeutics focuses on Hepatocellular Carcinoma, Hepatocellular Carcinoma (HCC), Solid Tumor based on our analysis of their pipeline programs and drug development activities.